Genentech culls muscle-preserving drug in genetic diseases, raising questions about obesity trial
基因泰克砍掉用于遗传病的保肌药物，肥胖症试验前景引发疑问

Roche’s subsidiary Genentech has called off the late-stage development of a muscle-building drug in two rare genetic conditions, spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD).
罗氏(Roche)旗下的基因泰克(Genentech)已叫停一款用于两种罕见遗传病——脊髓性肌萎缩症和面肩肱肌营养不良症(FSHD)——的增肌药物的后期研发。